Evidence map›Paper›PMID 32917001›Full record

ReviewMolecules (Basel, Switzerland)2020

Thymol and Thyme Essential Oil-New Insights into Selected Therapeutic Applications.

Adam Kowalczyk, Martyna Przychodna, Sylwia Sopata, Agnieszka Bodalska, Izabela Fecka

Registry-linked trialAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07030855 (Assessing the Efficacy of Elixirium Thymi Compositum in the Treatment of Acute Bronchitis in Pediatric Patients), which is not on this map. Cited by 181 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
181citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07030855 phase4enrolling by invitationnot on this mapstarted 2025, after this paper: background citation

Assessing the Efficacy of Elixirium Thymi Compositum in the Treatment of Acute Bronchitis in Pediatric Patients (EXOTIC): A Double-blind, Randomized, Placebo-controlled, Phase 4 Study

TypeinterventionalSponsorSemmelweis UniversityRan2025 to 2027Enrolled56ConditionsAcute BronchitisArmsElixirium thymi compositum (FoNo VIII.), Elixirium thymi compositum (FoNo VIII.) placebo
3 · Its place in the literature

Who cites it

181 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. ManagingMolecules (Basel, Switzerland) · 2025
    Pooled it
  3. Pooled it
  4. The Antiviral Potential ofMolecules (Basel, Switzerland) · 2024
    Pooled it
  5. Thymol and carvacrol againstFrontiers in pharmacology · 2024
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Review
  10. Review
  11. Review
  12. Antibiotics (Basel, Switzerland) · 2026
    Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Green synthesis of ZnO/FeRSC advances · 2026
    Article
  20. Article

121 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Adam KowalczykDepartment of Pharmacognosy and Herbal Medicines, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland.ORCID 0000-0002-7179-2549
Martyna PrzychodnaStudent's Scientific Group of Department of Pharmacognosy and Herbal Medicines, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland.
Sylwia SopataStudent's Scientific Group of Department of Pharmacognosy and Herbal Medicines, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland.
Agnieszka BodalskaDepartment of Pharmacognosy and Herbal Medicines, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland.
Izabela FeckaDepartment of Pharmacognosy and Herbal Medicines, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland.ORCID 0000-0002-1139-4581

Funding

Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu LPRN.Z500.20.001
6 · The paper itself

Abstract

Thymol (2-isopropyl-5-methylphenol) belongs to the phenolic monoterpenes and mostly occurs in thyme species. It is one of the main compounds of thyme essential oil. Both thymol and thyme essential oil have long been used in traditional medicine as expectorant, anti-inflammatory, antiviral, antibacterial, and antiseptic agents, mainly in the treatment of the upper respiratory system. The current search for new directions of biological or therapeutic activities of natural plant substances with known structures includes thyme essential oil and thymol. Novel studies have demonstrated their antibiofilm, antifungal, antileishmanial, antiviral, and anticancer properties. Also, their new therapeutic formulations, such as nanocapsules containing these constituents, can be beneficial in medicinal practice and create opportunities for their extensive use. Extensive application of thymol and thyme essential oil in the healthcare sector is very promising but requires further research and analysis.

Indexed as

AnimalsAnti-Bacterial AgentsAntifungal AgentsAntiparasitic AgentsAntiviral AgentsApoptosisBiofilmsCell ProliferationCryptococcusHumansMicrobial Sensitivity TestsMonoterpenesOils, VolatilePhenolsPlant ExtractsPlant OilsAnti-Bacterial AgentsAntifungal AgentsAntiparasitic AgentsAntiviral AgentsMonoterpenesOils, VolatilePhenolsPlant ExtractsPlant OilsPolymersThymolnew therapeutic applicationsthyme essential oilthymol

Identifiers

PMID32917001
PMCPMC7571078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.